Liquidia (LQDA) Total Non-Current Liabilities (2019 - 2026)

Liquidia's (LQDA) quarterly Total Non-Current Liabilities came in at $284.4 million in Q1 2026, up 67.12% year-on-year from $170.2 million in Q1 2025, and up 3.5% quarter-over-quarter from $274.8 million in Q4 2025.

Liquidia (LQDA) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends

Liquidia's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $284.4 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 67.12% year-over-year to $284.4 million in Q1 2026; TTM through Mar 2026 was $284.4 million, a 67.12% increase from a year earlier, with the FY2025 full-year figure at $274.8 million, up 91.32% from the prior year.
  • Total Non-Current Liabilities advanced to $284.4 million in Q1 2026 per LQDA's latest filing, from $274.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $284.4 million in Q1 2026 and bottomed at $30.5 million in Q2 2022.
  • The 5-year median for Total Non-Current Liabilities is $93.3 million (2024), against an average of $119.4 million.
  • Across the five-year window, Total Non-Current Liabilities increased 28.22% in 2023 and surged 137.43% in 2024, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $32.2 million in 2022, then soared by 99.9% to $64.3 million in 2023, then surged by 123.27% to $143.6 million in 2024, then soared by 91.32% to $274.8 million in 2025, then gained by 3.5% to $284.4 million in 2026.
  • Per Business Quant, the three latest LQDA Total Non-Current Liabilities figures stand at $284.4 million (Q1 2026), $274.8 million (Q4 2025), and $245.6 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 Liquidia 7.84 Bn 7.61 Bn 121.79 Mn 284.41 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 284.41 Mn
Dec 31, 2025 274.80 Mn
Sep 30, 2025 245.65 Mn
Jun 30, 2025 234.25 Mn
Mar 31, 2025 170.18 Mn
Dec 31, 2024 143.64 Mn
Sep 30, 2024 135.17 Mn
Jun 30, 2024 107.71 Mn
Mar 31, 2024 93.30 Mn
Dec 31, 2023 64.33 Mn
Sep 30, 2023 56.93 Mn
Jun 30, 2023 54.25 Mn
Mar 31, 2023 40.67 Mn
Dec 31, 2022 32.18 Mn
Sep 30, 2022 30.97 Mn
Jun 30, 2022 30.46 Mn
Mar 31, 2022 31.72 Mn
Dec 31, 2021 22.32 Mn
Sep 30, 2021 22.26 Mn
Jun 30, 2021 22.36 Mn